

April/May 2012 ♦ Produced by The Prescribing Team

## NHSGGC Prescribing Indicators 2012/13

These indicators have been developed over several months with involvement from acute clinicians, GPs and pharmacists with final agreement through the Prescribing management Group and the Local Medical Committee.

Last year's Quality Programme (QP) Prescribing Indicators encouraged an evaluation of prescribing across Scotland. With the removal of the prescribing component of QP the SGHD were keen to continue having a national focus on prescribing and have developed National Therapeutic Indicators (NTIs). This Scottish Quality Prescribing Initiative (PCA(M)(2012)08) will compliment the existing QOF indicators relating to prescribing actions (MED 6 & 10) and encourage practices to implement prescribing change in up to 2 areas.

The Rational Prescribing Indicator (RPI) scheme remains with funding by NHSGGC for the additional work the same as last year. The aim is to promote quality and cost effective improvements in prescribing.

The table below shows the baseline data period and the final data period for measuring the changes for each of the indicator types:

Indicator Type	Baseline Period	Final Measurement Period
RPI	Oct-Dec 2011	Oct-Dec 2012
GMS MED 6 & 10	Oct-Dec 2011	Jan-Mar 2013
NTIs	Jan-Mar 2012	Jan-Mar 2013

The indicators for the financial year 2012/2013 are as follows:

Indicator & Measure	Target	Target Shift
<b>GASTROINTESTINAL</b>		
Proton pump inhibitors (DDD per 1000 weighted patients per day)*	98.67	5.14 ▼
High strength oral PPIs as a % of all oral PPIs (DDD)*	3.24%	0.77% ▼
Generic lansoprazole and omeprazole capsules as a % of all single agent oral PPIs (Items)	94.18%	0.75% ▲
Omeprazole capsules as a % of all omeprazole (excluding MUPS®) (DDD)	99.79%	0.17% ▲
Gaviscon® Advance 500ml to Peptac® 500ml (Quantity)	80% switch	n/a
Movicol® (excluding paediatric) to Laxido® (Quantity)	80% switch	n/a
Cimetidine 400mg & 800mg tabs to ranitidine 150mg & 300mg tabs (Quantity)	100% switch	n/a

<b>CARDIOVASCULAR</b>		
Simvastatin, atorvastatin and pravastatin as a % of all statins (DDD)*	99.12%	0.42% ▲
Generic amlodipine maleate/mesilate as a % of all prescribing of amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nifedipine and nisoldipine (ie dihydropyridine calcium-channel blockers) (Items)	87.58%	2.08% ▲
Generic doxazosin standard release tablets as a percentage of all doxazosin (Items)	97.12%	3.58% ▲
Generic ISMN standard release tablets as a percentage of all ISMN (Items)	87.30%	3.22% ▲
Dipyridamole MR 200mg (DDD per 1000 weighted patients per day)*	2.39	0.45 ▼
Omega-3-acid ethyl esters (Quantity per 1000 weighted patients per day)	0.12	0.28 ▼
Ezetimibe, including combinations, as a % of all ezetimibe, including combinations, and statins (DDD)*	0.48%	0.22% ▼
Ezetimibe (including combinations) (DDD per 1000 weighted patients per day)	0.74	0.29 ▼
Ramipril tabs to ramipril caps (Quantity)	100% switch	n/a
<b>RESPIRATORY</b>		
High strength steroid inhalers as a % of all inhalers in BNF Sections 3.1 and 3.2 (Items)*	11.03%	1.05% ▼
Leukotriene receptor antagonists (Items per 1000 patients)	4.67	1.05 ▼
Mucolytics (Items per 1000 weighted patients)	4.29	1.24 ▼
<b>CNS (PSYCHOTROPICS)</b>		
Hypnotics and anxiolytics (BNF 4.1.1 and 4.1.2) (DDD per 1000 weighted patients per day)*	14.43	3.89 ▼
Buspirone (Cost per 1000 weighted patients per day)	£0.00	£0.10 ▼
Fluoxetine, citalopram and sertraline as a % of all SSRIs, duloxetine, mirtazapine, reboxetine and venlafaxine (Items)	75.16%	1.50% ▲
Escitalopram as a % of all SSRIs (Items)	1.04%	0.41% ▼
Generic standard release venlafaxine as a % of all solid dose venlafaxine (Items)	49.21%	5.25% ▲
Review of antidepressants - % of those on repeat prescription for antidepressants who have had a medication review in the last 2 years	n/a	n/a
Quetiapine SR as a % of all quetiapine (Items)	8.06%	5.66% ▼
Lormetazepam or 1mg loprozalam to zopiclone (Quantity)	60% switch	n/a
Amisulpride 400mg tabs to 2 x amisulpride 200mg tabs (Quantity)	50% switch	n/a
Fluoxetine 60mg caps to 3 x fluoxetine 20mg caps (Quantity)	100% switch	n/a

<b>CNS (PAIN)</b>		
Opioids (BNF 4.7.2, co-codamol 30/500, co-dydramol 20/500 and 30/500, and Tramacet®) (Items per 1000 weighted patients per day)	1.60	0.18 ▼
Oxycodone and morphine (DDD per 1000 weighted patients per day)	1.58	0.39 ▼
Oxycodone as a % of all oxycodone and morphine (DDD)	21.99%	5.93% ▼
Tramadol (and combinations) (DDD per 1000 weighted patients per day)	7.5	0.98 ▼
Fentanyl (excluding injections) (DDD per 1000 weighted patients per day)	0.15	0.21 ▼
Buprenorphine patches (DDD per 1000 weighted patients per day)	0.11	0.08 ▼
Lidocaine patches (Items per 1000 weighted patients per day)	0.2	0.29 ▼
Pregabalin and gabapentin (Cost per 1000 weighted patients per day)	£7.51	£1.17 ▼
Oral triptans (DDD per 1000 weighted patients per day)	0.51	0.13 ▼
Gabapentin 600mg and 800mg tabs to 2 x 300mg and 2 x 400mg gabapentin caps (Quantity)	90% switch	n/a
Propranolol 80mg and 160mg modified-release caps to propranolol 80mg standard release tabs (Quantity)	80% switch	n/a
<b>ANTI-INFECTIVES</b>		
Antibacterial drugs (Items per 1000 patients per day)*	1.82	0.13 ▼
Quinolones (DDD per 1000 patients per day)	0.42	0.11 ▼
4C antibacterial drugs (Items per 1000 patients per day)*	14.11	2.34 ▼
<b>DIABETES</b>		
Metformin and sulphonylureas as a % of all antidiabetic drugs (BNF 6.1.2) (DDD)*	91.06%	1.37% ▲
Long-acting insulin analogues (detemir and glargine) as a % of all intermediate and long-acting insulins (excluding biphasic insulins) (DDD)	48.23%	4.07% ▼
Exenatide as a % of all glucagon-like peptide-1 prescribing (DDD)	47.06%	9.41% ▲
Glucagon-like peptide-1 (DDD per 1000 weighted patients per day)	0.62	0.20 ▼
Metformin solution 100ml to 20 x metformin 500mg tablets (reduction in metformin solution) (Quantity)	100% reduction	n/a
Med Level 1 review of consumables prescribed for the management of diabetes	n/a	n/a
<b>UROLOGY</b>		
Generic finasteride as a % of all prescribing of finasteride and dutasteride (Items)	92.48%	3.06% ▲
Antimuscarinics (BNF 7.4.2) (DDD per 1000 weighted patients per day)	7.96	0.76 ▼

<b>MUSCULOSKELETAL, ANTI-INFLAMMATORIES &amp; OSTEOPOROSIS</b>		
Cox-2s as a % of all oral NSAIDs including Cox-2s (Items)	2.09%	0.82% ▼
NSAIDs (all oral and injectable NSAIDs including Cox-2s) (DDD per 1000 weighted patients)	31.8	3.36 ▼
Generic Formulary recommended NSAID gel as a % of all topical NSAIDs (Items)	85.93%	7.53% ▲
Quinine (DDDs per 1000 weighted patients per day)*	0.74	0.15 ▼
<b>NUTRITION AND BLOOD</b>		
Sip feeds (Quantity per 1000 weighted patients per day)	2.33	0.38 ▼
Orlistat (DDDs per 1000 weighted patients per day)	0.41	0.17 ▼
<b>SKIN AND WOUNDS</b>		
Formulary wound dressing products as a % of all wound dressing products (Items)	83.40%	2.94% ▲
Antimicrobial wound dressing products as a % of all wound dressing products (Items)*	12.66%	1.61% ▼
Foam wound dressing products as a % of all wound dressing products (Items)	10.13%	1.97% ▼
<b>ENT</b>		
Preferred list drugs used in nasal allergy (beclometasone dipropionate and budesonide (Rhinocort Aqua®)) as a % of all drugs used in nasal allergy (BNF 12.2.1) (Items)	51.24%	5.01% ▲

\* An update will be provided on NTIs in June 2012 when baseline data is available and the details have been finalised for these indicators. In the meantime, please refer to the NHS Scotland circular on Scottish Quality Prescribing Initiative for more information ([http://www.sehd.scot.nhs.uk/pca/PCA2012\(M\)08.pdf](http://www.sehd.scot.nhs.uk/pca/PCA2012(M)08.pdf)).

## 2013 Onwards

Later this year more detailed prescribing information will become available from iSD. This will allow a more targeted approach to the development of prescribing indicators with the opportunity to develop increasingly patient-focused indicators.

This time next year it is anticipated that several of these new styled indicators will be developed for use across NHSGGC more accurately reflecting prescribing practice.

## Medicines Management LES 2012/13

The Practice Medicines Management LES for the coming year has been approved and started 7<sup>th</sup> May 2012. The updated MMLES builds upon the positive work undertaken by practices to date. The new version is similar but some refinements include:

- a practice led repeat prescribing review to reduce waste and improve efficiency
- an enhanced level 1 med review to improve ambiguous directions and compliance issues
- working to improve the reporting of selected non-formulary drugs and facilitate discussion with secondary care

Resource materials should be available shortly via the MMLES StaffNet website. These will include updated guidance, an EMIS/Vision compatible database and an electronic reporting tool. Contact [prescribingteams@ggc.scot.nhs.uk](mailto:prescribingteams@ggc.scot.nhs.uk) for further information.